Literature DB >> 17197305

Porous tantalum implant in early osteonecrosis of the hip: preliminary report on operative, survival, and outcomes results.

Michael S Shuler1, Michael D Rooks, James R Roberson.   

Abstract

Porous tantalum implants are used in early osteonecrosis of the hip. Device evaluation included surgical time, blood loss, hospitalization, patient-controlled analgesia use, transfusions, implant survival, and outcomes. Mean blood loss was 70 mL. Mean operative time was 36 minutes. Average hospitalization was less than 1 day. No patient required patient-controlled analgesia use or transfusions. Results were compared to a historical vascularized fibular graft population. All parameters were less than the fibular graft groups (P < .00001). All surviving implants (86%) resulted in good to excellent outcomes. Kaplan-Meier analysis at 39 months was 86% and 67% for the implant and fibular graft, respectively (P = .21). Early outcomes demonstrate that porous tantalum implants are a safe option for femoral head salvage. Continued follow-up is necessary to determine the long-term success.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17197305     DOI: 10.1016/j.arth.2006.03.007

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  45 in total

1.  The use of an injectable calcium sulphate/calcium phosphate bioceramic in the treatment of osteonecrosis of the femoral head.

Authors:  Roberto Civinini; Pietro De Biase; Christian Carulli; Fabrizio Matassi; Lorenzo Nistri; Rodolfo Capanna; Massimo Innocenti
Journal:  Int Orthop       Date:  2012-03-17       Impact factor: 3.075

2.  Clinical and radiological outcome of the treatment of osteonecrosis of the femoral head using the osteonecrosis intervention implant.

Authors:  Thilo Floerkemeier; Fritz Thorey; Dorothea Daentzer; Matthias Lerch; Phillip Klages; Henning Windhagen; Gabriela von Lewinski
Journal:  Int Orthop       Date:  2010-01-30       Impact factor: 3.075

3.  Core decompression and osteonecrosis intervention rod in osteonecrosis of the femoral head: clinical outcome and finite element analysis.

Authors:  Thilo Floerkemeier; André Lutz; Udo Nackenhorst; Fritz Thorey; Hazibullah Waizy; Henning Windhagen; Gabriela von Lewinski
Journal:  Int Orthop       Date:  2010-10-24       Impact factor: 3.075

Review 4.  Properties of open-cell porous metals and alloys for orthopaedic applications.

Authors:  Gladius Lewis
Journal:  J Mater Sci Mater Med       Date:  2013-07-13       Impact factor: 3.896

5.  A modified porous tantalum implant technique for osteonecrosis of the femoral head: survivorship analysis and prognostic factors for radiographic progression and conversion to total hip arthroplasty.

Authors:  Yaosheng Liu; Xiuyun Su; Shiguo Zhou; Lei Wang; Cheng Wang; Shubin Liu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

6.  A current review of core decompression in the treatment of osteonecrosis of the femoral head.

Authors:  Todd P Pierce; Julio J Jauregui; Randa K Elmallah; Carlos J Lavernia; Michael A Mont; James Nace
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

Review 7.  [Joint-preserving operative treatment of avascular necrosis of the femoral head].

Authors:  C Lüring; C Benignus; J Beckmann
Journal:  Orthopade       Date:  2018-09       Impact factor: 1.087

8.  Tantalum rod implantation for femoral head osteonecrosis: survivorship analysis and determination of prognostic factors for total hip arthroplasty.

Authors:  Yaosheng Liu; Liang Yan; Shiguo Zhou; Xiuyun Su; Yuncen Cao; Cheng Wang; Shubin Liu
Journal:  Int Orthop       Date:  2015-08-11       Impact factor: 3.075

9.  Management of avascular necrosis of femoral head at pre-collapse stage.

Authors:  Ramesh Kumar Sen
Journal:  Indian J Orthop       Date:  2009-01       Impact factor: 1.251

10.  Outcome after tantalum rod implantation for treatment of femoral head osteonecrosis: 26 hips followed for an average of 3 years.

Authors:  Sokratis E Varitimidis; Apostolos P Dimitroulias; Theophilos S Karachalios; Zoe H Dailiana; Konstantinos N Malizos
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.